Clinical Trial

Investigation of Cardioversion Versus Therapeutic Ablation for Persistent AF (ORBICA-AF)

Study acronym: ORBICA-AF
Recruiting
View on ClinicalTrials.gov →
Summary
The main aim of the research is to investigate whether patients undergoing pulmonary vein isolation with catheter ablation for persistent atrial fibrillation (AF) will have lower rates of AF recurrence than those treated by DC cardioversion without an ablation procedure.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-10-19; most recent amendment 2025-09-01.
Status change: Not Yet Recruiting → Recruiting 2024-08-22
Trial Details
NCT Number NCT06096246
Lead Sponsor Barts & The London NHS Trust
Conditions Persistent Atrial Fibrillation, Cardiac Arrhythmia, Catheter Ablation
Enrollment 208 participants
Start Date 2024-07-26
Primary Completion 2027-07-26 (estimated)
Study Completion 2027-12-05 (estimated)
Updated on ClinicalTrials.gov 2025-09-03